Population pharmacokinetic analysis of linezolid in patients with different types of shock: Effect of platelet count

Wang,Dongdong; Zheng,Xiaofei; Yang,Yang; Chen,Xiao

doi:10.3892/etm.2019.7747

Population pharmacokinetic analysis of linezolid in patients with different types of shock: Effect of platelet count

Authors:
- Dongdong Wang
- Xiaofei Zheng
- Yang Yang
- Xiao Chen
View Affiliations

Affiliations: Department of Pharmacy, Children's Hospital of Fudan University, Shanghai 201102, P.R. China, Department of Medical Imaging, Zhongda Hospital Affiliated to Southeast University, Nanjing, Jiangsu 210000, P.R. China, Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, Jiangsu 221004, P.R. China, Department of Pharmacy, The People's Hospital of Jiangyin, Jiangyin, Jiangsu 214400, P.R. China
Published online on: July 8, 2019 https://doi.org/10.3892/etm.2019.7747
Pages: 1786-1792
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Linezolid was approved by the Food and Drug Administration for the treatment of serious infections. However, patients with serious frequently develop shock, and it is currently elusive whether shock affects the pharmacokinetics of linezolid. The aim of the present study was to explore whether the pharmacokinetics of linezolid are different among patients with various types of shock or patients without shock and whether potential confounders are involved in their outcomes. A population pharmacokinetic analysis using a non‑linear mixed‑effects model was performed to examine the pharmacokinetics of patients with different types of shock or patients without shock. The pharmacokinetics of linezolid in patients with different types of shock or patients without shock was described by a one‑compartment model. In our results, the patients with different types of shock or patients without shock demonstrated no differences in pharmacokinetics, whereas the platelet count was identified as a significant influencing factor. The results demonstrated that the pharmacokinetics of linezolid exhibited no significant differences among patients with different types of shock or patients without shock, whereas the platelet count significantly affected the clearance rate of linezolid.

View Figures

View References

1	Ashtekar DR, Costa-Periera R, Shrinivasan T, Iyyer R, Vishvanathan N and Rittel W: Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn Microbiol Infect Dis. 14:465–471. 1991. View Article : Google Scholar : PubMed/NCBI
2	Jones RN, Johnson DM and Erwin ME: In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother. 40:720–726. 1996. View Article : Google Scholar : PubMed/NCBI
3	Kaatz GW and Seo SM: In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother. 40:799–801. 1996. View Article : Google Scholar : PubMed/NCBI
4	Meagher AK, Forrest A, Rayner CR, Birmingham MC and Schentag JJ: Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother. 47:548–553. 2003. View Article : Google Scholar : PubMed/NCBI
5	Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T and Rom WN: Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest. 134:187–192. 2008. View Article : Google Scholar : PubMed/NCBI
6	Fortun J, Martin-Davila P, Navas E, Perez-Elias MJ, Cobo J, Tato M, De la Pedrosa EG, Gomez-Mampaso E and Moreno S: Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother. 56:180–185. 2005. View Article : Google Scholar : PubMed/NCBI
7	Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, Kim WD and Shim TS: Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother. 58:701–704. 2006. View Article : Google Scholar : PubMed/NCBI
8	Cynamon MH, Klemens SP, Sharpe CA and Chase S: Activities of several novel oxazolidinones against mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother. 43:1189–1191. 1999. View Article : Google Scholar : PubMed/NCBI
9	Molicotti P, Ortu S, Bua A, Cannas S, Sechi LA and Zanetti S: In vitro efficacy of Linezolid on clinical strains of Mycobacterium tuberculosis and other mycobacteria. New Microbiol. 29:275–280. 2006.PubMed/NCBI
10	Sood R, Bhadauriya T, Rao M, Gautam R, Malhotra S, Barman TK, Upadhyay DJ and Rattan A: Antimycobacterial activities of oxazolidinones: A review. Infect Disord Drug Targets. 6:343–354. 2006. View Article : Google Scholar : PubMed/NCBI
11	Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, Nicolau DP and Kuti JL: Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrob Agents Chemother. 55:3393–3398. 2011. View Article : Google Scholar : PubMed/NCBI
12	Sazdanovic P, Jankovic SM, Kostic M, Dimitrijevic A and Stefanovic S: Pharmacokinetics of linezolid in critically ill patients. Expert Opin Drug Metab Toxicol. 12:595–600. 2016. View Article : Google Scholar : PubMed/NCBI
13	Buerger C, Plock N, Dehghanyar P, Joukhadar C and Kloft C: Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother. 50:2455–2463. 2006. View Article : Google Scholar : PubMed/NCBI
14	Calzada Y, Jordan I, Vila-Perez D, Cambra FJ and Munoz-Almagro C: Pleuropneumonia and septic shock due to multiresistant Streptococcus pneumoniae serotype 19A treated with linezolid. An Pediatr (Barc). 81:e22–23. 2014.(In Spanish). View Article : Google Scholar : PubMed/NCBI
15	De Bels D, Garcia-Filoso A, Jeanmaire M, Preseau T, Miendje Deyi VY and Devriendt J: Successful treatment with linezolid of septic shock secondary to methicillin-resistant Staphylococcus aureus arthritis. J Antimicrob Chemother. 55:812–813. 2005. View Article : Google Scholar : PubMed/NCBI
16	Rac H, Bojikian KD, Lucar J and Barber KE: Successful treatment of necrotizing fasciitis and streptococcal toxic shock syndrome with the addition of linezolid. Case Rep Infect Dis. 2017:57207082017.PubMed/NCBI
17	Stevens DL, Wallace RJ, Hamilton SM and Bryant AE: Successful treatment of staphylococcal toxic shock syndrome with linezolid: A case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin Infect Dis. 42:729–730. 2006. View Article : Google Scholar : PubMed/NCBI
18	Wang DD, Lu JM, Li Q and Li ZP: Population pharmacokinetics of tacrolimus in paediatric systemic lupus erythematosus based on real-world study. J Clin Pharm Ther. 43:476–483. 2018. View Article : Google Scholar : PubMed/NCBI
19	Vadcharavivad S, Praisuwan S, Techawathanawanna N, Treyaprasert W and Avihingsanon Y: Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: Comparison with similar data from other populations. J Clin Pharm Ther. 41:310–328. 2016. View Article : Google Scholar : PubMed/NCBI
20	Sahuquillo Arce JM, Colombo Gainza E, Gil Brusola A, Ortiz Estevez R, Canton E and Gobernado M: In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev Esp Quimioter. 19:252–257. 2006.PubMed/NCBI
21	Sweeney MT and Zurenko GE: In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms. Antimicrob Agents Chemother. 47:1902–1906. 2003. View Article : Google Scholar : PubMed/NCBI
22	Beitdaghar M, Ahmadrajabi R, Karmostaji A and Saffari F: In vitro activity of linezolid alone and combined with other antibiotics against clinical enterococcal isolates. Wien Med Wochenschr. 169:215–221. 2019. View Article : Google Scholar : PubMed/NCBI
23	Craig WA: Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 17:479–501. 2003. View Article : Google Scholar : PubMed/NCBI
24	Roger C, Muller L, Wallis SC, Louart B, Saissi G, Lipman J, Lefrant JY and Roberts JA: Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: Comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration. J Antimicrob Chemother. 71:464–470. 2016. View Article : Google Scholar : PubMed/NCBI
25	Rayner CR, Forrest A, Meagher AK, Birmingham MC and Schentag JJ: Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet. 42:1411–1423. 2003. View Article : Google Scholar : PubMed/NCBI
26	Wang DD, Lu JM, Li YZ, Li Q and Li ZP: Population pharmacokinetics of sirolimus in pediatric tuberous sclerosis complex: From real world study. Int J Clin Exp Med. 11:12302–12309. 2018.
27	Chen Y, Wu D, Dong M, Zhu Y, Lu J, Li X, Chen C and Li Z: Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants. Eur J Clin Pharmacol. 74:921–930. 2018. View Article : Google Scholar : PubMed/NCBI
28	Gong Y, Chen Y, Li Q and Li Z: Population pharmacokinetic analysis of digoxin in Chinese neonates and infants. J Pharmacol Sci. 125:142–149. 2014. View Article : Google Scholar : PubMed/NCBI
29	Li Z, Chen Y, Li Q, Cao D, Shi W, Cao Y, Wu D, Zhu Y, Wang Y and Chen C: Population pharmacokinetics of piperacillin/tazobactam in neonates and young infants. Eur J Clin Pharmacol. 69:1223–1233. 2013. View Article : Google Scholar : PubMed/NCBI
30	Andrews LM, Hesselink DA, van Gelder T, Koch BC, Cornelissen EA, Bruggemann RJ, van Schaik RH, de Wildt SN, Cransberg K and de Winter BC: A population pharmacokinetic model to predict the individual starting dose of tacrolimus following pediatric renal transplantation. Clin Pharmacokinet. 57:475–489. 2018. View Article : Google Scholar : PubMed/NCBI
31	Yu ZC, Zhou PJ, Wang XH, Francoise B, Xu D, Zhang WX and Chen B: Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients. Acta Pharmacol Sin. 38:1566–1579. 2017. View Article : Google Scholar : PubMed/NCBI
32	Chen B, Shi HQ, Liu XX, Zhang WX, Lu JQ, Xu BM and Chen H: Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients. J Clin Pharm Ther. 42:679–688. 2017. View Article : Google Scholar : PubMed/NCBI
33	Chevillard L, Sabo N, Tod M, Labat L, Chasport C, Chevaleyre C, Thibaut F, Barre J, Azuar J, Questel F, et al: Population pharmacokinetics of oral baclofen at steady-state in alcoholic-dependent adult patients. Fundam Clin Pharmacol. 32:239–248. 2018. View Article : Google Scholar : PubMed/NCBI
34	Plock N, Buerger C, Joukhadar C, Kljucar S and Kloft C: Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab Dispos. 35:1816–1823. 2007. View Article : Google Scholar : PubMed/NCBI